How to prepare an application for revision of a CEP

Size: px
Start display at page:

Download "How to prepare an application for revision of a CEP"

Transcription

1 How to prepare an application for revision of a CEP P.Poukens-Renwart, PhD Certification of Substances Division EDQM

2 Summary Validity of a CEP Revision background Types of revisions and examples How to prepare the application for revision When are CEPs revised and what to do when a revision is approved

3 Validity of CEP Once your CEP has been granted it must be maintained throughout its lifetime!

4 Basic principles for maintaining a CEP Any change (administrative or technical) must be reported to EDQM for approval Original CEP: valid 5 years. Holder needs to apply for renewal in time (6 months before expiry) After renewal, CEP valid for an unlimited period, provided the dossier is kept up-to-date In all cases, holder to inform customers of the change Revised CEP to be sent to customers

5 Revisions of CEPs: Background Based on EU Regulations on Variations to Marketing Applications Specific guidelines for revisions of CEPs: Guideline on requirements on revision / renewal of CEPs (PA/PH/CEP (04) 2 4R) New procedures for management of revision / renewal of CEPs (PA/PH/Exp. CEP/T (04) 18 2R)

6 Types of changes Notifications Minor changes Major changes Renewal (after 5 years) Update following revision of the monograph or regulatory change NB: Possibility to group variations

7 Notification: Do and Tell principle Immediate notifications (IN) or Annual Notifications (AN) (to be submitted within 12 months after implementation) Timescale : 1 month

8 Workflow for Notification No Acknowledgement of Receipt Letter sent to advise that either the notification has been accepted as valid or has been rejected. No request for additional information Revised CEP only issued when the information on the CEP is changed (i.e.name and address)

9 Minor Change Minor change is by default => No conditions Some typical minor changes listed in the guideline: Timescales : Single Multiple or grouped 30 days 60 days

10 Workflow for minor changes Acknowledgement of Receipt sent within 5 days One request for additional information sent if necessary Holder has 30 days to respond to this request EDQM has 30 days to evaluate the response EDQM feed-back: Notice of approval or revised CEP issued request for revision rejected

11 Major Changes Timescale 60 days Workflow: Acknowledgement of Receipt sent within 5 day One request for additional information sent if necessary Holder has 30 days to answer this request EDQM has 30 days to evaluate the response EDQM feed-back: o Revised CEP issued o Request for revision rejected

12 Update after Monograph Revision Initiated by EDQM: when a revised monograph is published, EDQM sends request for data (either demonstration of compliance or suitability of the monograph) Holder asked to supply the requested information within 3 months (it is mandatory to answer) Response assessed within 3 months EDQM feed-back: o Approval o Revised CEP issued (if the information on the CEP changes)

13 Renewal Holder to apply about 6 months before expiry The following documentation should be provided: Declaration that no change has occurred since the last revision OR In case of changes included in the request (no major changes): updated dossier (CTD) comprehensive list of changes supportive data Timescale 3 months

14 Workflow for Renewal Acknowledgement of Receipt sent within 5 days If request for additional information sent - Holder has 30 days to respond to this demand - EDQM has 30 days to evaluate the response If holder applied in time and evaluation on-going at expiry date: the CEP will be temporarily renewed unless there is an unresolved issue with the dossier EDQM feed-back: Renewed CEP issued (if assessment finalised before expiry) Revised CEP issued (if conclusion of assessment invalids temporarily renewed CEP).

15 Assessment of Renewal dossiers Compliance with General Monograph 2034 Substances for Pharmaceutical Use Compliance with recent European quality guidelines: e.g. impurities, residual solvents, residual catalysts Any declared changes Not an administrative job!

16 Submission of a notification / revision Each submission should be composed of the following modules Module 1: Cover letter describing the request Application form Supporting documentation Module 3: All updated section of the dossier

17 Module 1: application form : Give appropriate administrative information Select type of revision in the classification table (notification or major revision) or detail the specific minor revision Select the corresponding revision(s) on the invoicing sheet Sign the commitment to inform your customers in case of CEP revision, CEP suspension, withdrawal or negative outcome of an EDQM inspection Sign the commitment that you are informed and you accept that assessment reports may be shared with competent authorities NB: The signature of these commitments is part of the criteria for validating the applications at receipt.

18 Application form : how to fill it? Specify the type of application by ticking ONE box: If Notif + minor => «minor» If Notif + major => «major» If Notif and/or minor + renewal => «renewal»

19 Application form: Names and addresses Give appropriate administrative information => reported on the CEP

20 Application form: specific information Tick the type of notifications (INx, ANx) and specify implementation date for Annual notification Tick the type of major change

21 Application form: specific information When applying for minor change(s) please select or give details related to these not listed changes! AN4: minor change to the manufacturing process should not be reported in this box

22 Application form: invoicing details Item selected should be in line with selection under 1.2 type of application.

23 Module 1: Supporting documentation A complete list of the changes + brief summary For notifications : confirmation that all conditions of EDQM guideline are fulfilled For minor or major revisions : justification of the classification + supportive data (comparative tables, declarations, discussion on impurity carry-over, batch data...) and/or reference to the relevant parts of the dossier where information is to be found.

24 Module 3: Updated sections of the dossier Sections impacted by the changes Sections should be complete and in line with the original granularity of the dossier Annexes should be avoided (info should be included in Module 1 and also in the relevant sections

25 Some examples

26 Changes related to the manufacturing process A synthetic route is characterized by the starting materials, intermediates and process steps, and also by the reagents, the solvents and any catalysts used for the synthesis. A declaration stating that the synthetic route remains unchanged implies that all these elements remain the same. Declarations that the route is essentially the same are not acceptable :any difference between the approved and proposed synthetic routes has to be detailed and discussed.

27 Changes related to the manufacturing process = Notification when all conditions listed in the guideline are fulfilled (covers mainly minor changes to quantities of materials or operating conditions) = Major revision if there is any substantial change to the synthetic route which may impact the qualitative and quantitative impurity profile of the final substance (e.g. any new solvent independently of its class, reagents, catalysts introduced or changed in the synthesis). = Minor revision (by default), if the request is neither a notification nor a major revision

28 Change to a manufacturer / manufacturing site for an intermediate or final substance: = Notification when the synthetic route, QC procedures and specs of the intermediate and final substance remain the same as those already approved and when the new manufacturer is of the same group as the approved manufacturer = Major revision when there is a change to the synthetic route, to the quality control procedures or to the specifications for the proposed manufacturer (or site) of an intermediate or for the proposed manufacturing site of the final substance = Minor revision (by default), if the request is not a major revision nor a notification

29 Change to a manufacturer of starting material: = Notification when the synthetic route, QC procedures and the specs of the SM remain the same as those already approved and when the new manufacturer is of the same group as the approved manufacturer. = Major revision when there is a change to the synthetic route, to QC procedures or to specs for the proposed manufacturer (common situation) = Minor revision (by default), if the request is not a major revision nor a notification

30 Changes to an analytical procedure: = Notification provided that the method remains essentially the same. NB: changes should be within the ranges allowed by the Ph. Eur general chapter Chromatographic separation techniques.! Any notification related to a test method appended to a CEP => revision of CEP. = Minor revision (by default), if the conditions for a notification are not met (Cross validation data required)

31 When are CEPs revised? After any notification/minor revisions impacting the content of CEP After any major revisions After renewal When conclusion of assessment of renewal invalids the temporarily renewed CEP at expiry

32 What to do after approval of a request for revision? What to do with a revised CEP? Provide a copy to customers Update of relevant Marketing Authorisation Applications Mandatory What to do when a change is approved but CEP is not revised? Inform customers Mandatory

33 Support to applicants Before preparing a request for revision Check EDQM website for: Published Guidelines & Notes (pages Revisions & Renewals) New guideline available on how to submit a request FAQs Contact EDQM for clarification (Helpdesk) Use Technical advice in case of doubt / complex schemes / specific questions

34 Acknowledgements My special thanks to Hélène Bruguera (Head of Certification Division at the EDQM) All my colleagues from the Certification Revision Team

35 QUESTIONS?

Revisions of CEPs. Basic principles for maintaining a CEP

Revisions of CEPs. Basic principles for maintaining a CEP Revisions of CEPs Nimet FILIZ Certification of Substances Department, EDQM Basic principles for maintaining a CEP Any change must be reported to EDQM for approval Original CEP is valid 5 years Holder needs

More information

The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme

The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme 18/10/2016 The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme Chinese & European Pharmacopoeias Workshop 17 October 2016

More information

Implementation of ICH Q3D in the Certification Procedure

Implementation of ICH Q3D in the Certification Procedure LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure

More information

Certification of suitability to the Monographs of the European Pharmacopoeia

Certification of suitability to the Monographs of the European Pharmacopoeia AMM/CB PUBLIC DOCUMENT (LEVEL 1) English only/anglais seulement Strasbourg, September 2018 Certification of suitability to the Monographs of the European Pharmacopoeia GUIDELINE ON REQUIREMENTS FOR REVISION/RENEWAL

More information

Variation Regulations (EU)

Variation Regulations (EU) Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current

More information

CEP submission: How to prepare a New Application?

CEP submission: How to prepare a New Application? CEP submission: How to prepare a New Application? Nathalie Vicente Certification of Substances Division Summary How to prepare a New Application? Requirements for a new CEP application Content of the dossier

More information

New Frontiers in the Quality of Medicines

New Frontiers in the Quality of Medicines New Frontiers in the Quality of Medicines Workshop Certification: How to use a Certificate (CEP) Moderators: Dr Jean-Louis Robert Prof Derek H. Calam EDQM International Conference 13-15 June 2007 Strasbourg,

More information

Proposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.

Proposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed. December 2008 Proposals for the Guideline on Classification of Variations Only those variations applicable to the active substance are listed. A variation which is not an extension and whose classification

More information

Implementation strategy of ICH Q3D guideline

Implementation strategy of ICH Q3D guideline 1 2 3 1 July 2016 EMA/404489/2016 Committee for Medicinal Products for Human use (CHMP) 4 5 Draft Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public

More information

English only/anglais seulement PA/PH/CEP (15) 31. Certification of suitability to the Monographs of the European Pharmacopoeia.

English only/anglais seulement PA/PH/CEP (15) 31. Certification of suitability to the Monographs of the European Pharmacopoeia. MMF/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/CEP (15) 31 Strasbourg, April 2018 Certification of suitability to the Monographs of the European Pharmacopoeia How to read a CEP Address:

More information

Materials Management Traceability, CEPs and managing non-conforming sites

Materials Management Traceability, CEPs and managing non-conforming sites Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain

More information

Implementation strategy of ICH Q3D guideline

Implementation strategy of ICH Q3D guideline 08 March 2017 EMA/CHMP/QWP/115498/2017 Committee for Medicinal Products for Human use (CHMP) Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public

More information

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations 30 June 2017 EMA/233564/2014 - Rev. 2 Procedure Management and Business Support Division European Medicines Agency practical guidance on the application form for centralised This document is intended as

More information

GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003

GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Final Revision 0 NOTICE TO

More information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION EN EN EN INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION Communication from the Commission Guideline on the details of the various categories of variations to the terms of marketing

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION 22.1.2010 Official Journal of the European Union C 17/1 (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGCIES EUROPEAN COMMISSION Communication from the Commission Guideline

More information

Content of the dossier for chemical purity and microbiological quality

Content of the dossier for chemical purity and microbiological quality Division Certification of Substances CP/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/ CEP (0) 1 R February 0 Certification of suitability of Monographs of the European Pharmacopoeia

More information

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...

More information

5. Changes to a CEP or to a confirmation of API-prequalification document 106

5. Changes to a CEP or to a confirmation of API-prequalification document 106 Annex 3 WHO guidelines on variations to a prequalified product Introduction 96 1. Background 97 1.1 Objectives 97 1.2 Scope and application 98 2. Guidance for implementation 99 2.1 s 99 2.1.1 Notifications

More information

Implementation of ICH Q3D in the Certification Procedure

Implementation of ICH Q3D in the Certification Procedure Implementation of ICH Q3D in the Certification Procedure PQRI/USP Workshop on ICH Q3D Elemental Impurities Requirements Recent Experience and Plans for Full Implementation in 2018 November 2-3, 2017 Cristian

More information

How to build a good CEP application - ICH Q3D

How to build a good CEP application - ICH Q3D How to build a good CEP application - ICH Q3D Lisa Moore B.Sc. (Pharm), MPSI Pharmaceutical Assessor, HPRA, Ireland External Expert CEP assessor. The place of the Certification Procedure in the global

More information

Wirkstoffdokumentation & CEP- Verfahren

Wirkstoffdokumentation & CEP- Verfahren Wirkstoffdokumentation & CEP- Verfahren Dr. Wolfgang Herzog AGES PharmMed, Institut Zulassung & Lifecycle Management AGES-Gespräch Am Pulsschlag des Arzneimittelwesens Das Institut LCM 25.11.2010 www.basg.at

More information

Official Journal C 223. of the European Union. Information and Notices. Information. Volume 56 2 August English edition

Official Journal C 223. of the European Union. Information and Notices. Information. Volume 56 2 August English edition Official Journal of the European Union ISSN 1977-091X C 223 English edition Information and Notices Volume 56 2 August 2013 Notice No Contents Page Information INFORMATION FROM EUROPEAN UNION INSTITUTIONS,

More information

The place of the Certification Procedure in the global regulatory environment

The place of the Certification Procedure in the global regulatory environment The place of the Certification Procedure in the global regulatory environment 19-20/09/2017 - Prague Workshop 1: how to build up a good CEP application Top ten deficiencies Cristian SAMPAOLESI Reference

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017) 23 October 2017 EMA/CVMP/QWP/502315/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary)

More information

What s most recent in EDQM Inspections?

What s most recent in EDQM Inspections? What s most recent in EDQM Inspections? IPA-EDQM-IPC Technical Conference Mumbai, 28 29 January 2010 Dr Andrew McMath Scientific Officer Certification of Substances Division Agenda EU requirements and

More information

Adopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016

Adopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016 1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological

More information

Guidelines. of

Guidelines. of EUROPEAN COMMISSION Brussels, 16.05.2013 C (2013) 2804 Guidelines of 16.05.2013 on the details of the various categories of variations, on the operation of the procedures laid down in Chapters, a, I and

More information

Post approval change of Japanese registration dossiers and impact on market supply

Post approval change of Japanese registration dossiers and impact on market supply Post approval change of Japanese registration dossiers and impact on market supply Table of content Table of content Business model evolution of API sales Challenge on Regulatory compliance Risks of Regulatory

More information

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION Page 1 of 13 May 2008 APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION HUMAN VETERINARY NATIONAL AUTHORISATION IN MRP MRP variation number 1A : / / / / / COMMUNITY AUTHORISATION EMEA variation number

More information

WHO guidelines on variations to a prequalified product

WHO guidelines on variations to a prequalified product Annex 3 WHO guidelines on variations to a prequalified product Introduction 96 1. Background 97 1.1 Objectives 97 1.2 Scope and application 98 2. Guidance for implementation 99 2.1 s 99 2.1.1 Notifications

More information

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 1. General questions Doc. Ref: CMDh/132/2009/Rev.20 May 2013 Question 1.1 What is the definition of MAH? According

More information

GUIDANCE ON VARIATIONS TO A PREQUALIFIED PRODUCT

GUIDANCE ON VARIATIONS TO A PREQUALIFIED PRODUCT May 2012 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 GUIDANCE ON VARIATIONS TO A PREQUALIFIED PRODUCT DRAFT FOR

More information

Workshop on Skip Testing

Workshop on Skip Testing 12-13 June 2018, Bern, Switzerland Workshop on Skip Testing Rosmarie Neeser Swissmedic, Inspectorates and Licences, Inspector Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 3000 Bern 9 Schweiz

More information

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations GUIDANCE ON AMENDMENTS TO AN ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) SUBMITTED IN SUPPORT OF A PREQUALIFIED PHARMACEUTICAL PRODUCT (FPP) OR PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENT (API)

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

Guide to Fees for Veterinary Products

Guide to Fees for Veterinary Products Guide to Fees for Veterinary Products FIN-G0003-16 2 JANUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

Medicines Variations Guideline

Medicines Variations Guideline Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:

More information

Medicine Variations Guideline

Medicine Variations Guideline Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:

More information

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide

More information

European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance

European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance Diana van Riet-Nales, Medicines Evaluation Board/NL NL CHMP/CVMP Quality Working Party delegate (humans) Former

More information

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances 3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for

More information

L 159/24 EN Official Journal of the European Union. COMMISSION REGULATION (EC) No 1085/2003. of 3 June 2003

L 159/24 EN Official Journal of the European Union. COMMISSION REGULATION (EC) No 1085/2003. of 3 June 2003 L 159/24 EN Official Journal of the European Union 27.6.2003 COMMISSION REGULATION (EC) No 1085/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for

More information

FAQ: Active Pharmaceutical Ingredient Master Files (APIMFs)

FAQ: Active Pharmaceutical Ingredient Master Files (APIMFs) (APIMFs) Electronic Formatting Will electronic signatures be accepted? Electronic signatures will be accepted on the basis that they form part of the submission and are therefore covered by declarations

More information

Quality Assessment & GMP Similarities & Differences

Quality Assessment & GMP Similarities & Differences Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences

More information

GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER

GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this

More information

SPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune

SPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved, 2010 1 Contents of the European Pharmacopoeia: nearly 2100 monographs

More information

EU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden

EU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden EU Regulatory Perspective and Expectations Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden Disclaimer EU regulators still have to build up an experience of applications based

More information

EMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only)

EMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only) EMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only) Doc. Ref.: CMDh/EMA/133/2010/Rev4 October 2010 INTRODUCTION AND GENERAL COMMENTS This document is intended to provide

More information

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline

More information

Legislative Framework and Scientific Guidance in European Assessment

Legislative Framework and Scientific Guidance in European Assessment Legislative Framework and Scientific Guidance in European Assessment Riccardo Luigetti Quality Assessors Training London 26 October 2009 1 Content of the presentation Scientific guidelines Other related

More information

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (13) 113 2R Evaluation and Reporting of Results Core document Full document title and reference Evaluation and Reporting of Results

More information

EN Official Journal of the European Union. (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003.

EN Official Journal of the European Union. (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003. L 159/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal

More information

Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries

Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,

More information

European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe

European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe Content Ph. Eur. Reference Standards General notices, terms and definitions Key attributes

More information

VOLUME 2A Procedures for marketing authorisation CHAPTER 2 Mutual Recognition. February 2007

VOLUME 2A Procedures for marketing authorisation CHAPTER 2 Mutual Recognition. February 2007 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/ BL D(2005) NOTICE TO APPLICANTS Revision 5 VOLUME 2A Procedures for marketing authorisation CHAPTER

More information

Pharmacopoeial Reference Standards

Pharmacopoeial Reference Standards Pharmacopoeial Reference Standards Industry view point Antony Raj Gomes Head- Quality Management 1 Presentation Overview Indian Industry an update Available guidelines Industry practices Current challenges

More information

Raw Material and Manufacturer Approval Procedure

Raw Material and Manufacturer Approval Procedure Raw Material and Manufacturer Approval Procedure National Health Regulatory Authority (NHRA) Kingdom of Bahrain May 2018 Version 1 1 1. Introduction This document is meant to provide assistance to industry

More information

Product. Commission. Information issued on. Notification 1. Decision. Issued 2 / affected 3 amended on

Product. Commission. Information issued on. Notification 1. Decision. Issued 2 / affected 3 amended on Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification 1 Decision Information issued on Issued 2 / affected

More information

Variations AGES MEA-LCM-QUAL. Mag. Caroline Kleber. Meet the Case Manager Vienna,

Variations AGES MEA-LCM-QUAL. Mag. Caroline Kleber. Meet the Case Manager Vienna, Mag. Caroline Kleber Meet the Case Manager Vienna, 9. 11. 2017 AGES MEA-LCM-QUAL Regulatory Background Commission Regulation (EC) No 1234/2008, amended by No 712/2012 Guidelines of 16.05.2013 on the details

More information

ICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options

ICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements

More information

Identification of the need and uses of a reference standard

Identification of the need and uses of a reference standard Identification of the need and uses of a reference standard Stefan Almeling Deputy Head of Laboratory Department, EDQM, Council of Europe TOPICS General / Definition Role in the monograph How established

More information

QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT

QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT Doc. Ref.: CMDh/274/2012, Rev3 NovemberRev4 December 2012 QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT... 1 Where can guidance and recommendations

More information

August 2018: Questions & Answers Botswana Medicines Regulatory Authority

August 2018: Questions & Answers Botswana Medicines Regulatory Authority S A Pharmaceutical Regulatory Affairs Association P O Box 2909 Randburg 2125 R.S.A. Telephone: + 27 (0) 11 852 5252 Telefax: + 27 (0) 865044927 Date: 06 August 2018 To: Chief Executive Officer: Botswana

More information

Current version 13 October 2016

Current version 13 October 2016 Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order

More information

GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS

GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda. Tel: +256-0414 - 255665/347391/2 E-mail:

More information

Manufacturers Meeting Copenhagen September 2012

Manufacturers Meeting Copenhagen September 2012 Manufacturers Meeting Copenhagen September 2012 Quality Assessment: Updates 1 Acronyms! API: active pharmaceutical ingredient CEP: EDQM certificate of suitability CTD: common technical document EC: expert

More information

Module 1: Administrative information Application form

Module 1: Administrative information Application form 7 September 2017 CMDh/332/2017/Rev.1 User guide for the electronic application form for a Marketing Authorisation Purpose and general rules This User guide has been prepared in order to facilitate the

More information

Current Hotspots during CMC Evaluation a European Regulatory Perspective

Current Hotspots during CMC Evaluation a European Regulatory Perspective www.pei.de Current Hotspots during CMC Evaluation a European Regulatory Perspective CMC Strategy Forum Japan 2018 3-4 December, Tokyo Steffen Gross, Head Section monoclonal - and polyclonal Antibodies

More information

Foreword. BABT 340 The Production Quality Certification Scheme for Manufacturers

Foreword. BABT 340 The Production Quality Certification Scheme for Manufacturers BABT 791 A Guide to the TUV SUD BABT Implementation of Module D (Production Quality Assurance) and Module E (Product Quality Assurance) of the Marine Equipment Directive A Certification Body of TÜV SÜD

More information

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL. Safety of the food chain Chemicals, contaminants, pesticides

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL. Safety of the food chain Chemicals, contaminants, pesticides EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Safety of the food chain Chemicals, contaminants, pesticides SANCO/12638/2011 20 November 2012 rev. 2 Guidance document on significant

More information

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways

More information

Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines

Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department

More information

Further information on the legislation can be found in all EU languages on EUR-LEX website:

Further information on the legislation can be found in all EU languages on EUR-LEX website: Making the railway system work better for society. 4 th Railway Package What is the 4 th Railway Package and its technical pillar? The 4 th Railway Package is a set of legislative texts designed to complete

More information

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016 EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials

More information

Guide to Registration of Persons Responsible for Placing In-vitro Diagnostic Medical Devices on the Market

Guide to Registration of Persons Responsible for Placing In-vitro Diagnostic Medical Devices on the Market Guide to Registration of Persons Responsible for Placing In-vitro Diagnostic Medical Devices on the Market AUT-G0053-1 17 JULY 2012 This guide does not purport to be an interpretation of law and/or regulations

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

Dangerous Goods Act 1985 Dangerous Goods (Transport by Road or Rail) Regulations 2008 [Part 18]

Dangerous Goods Act 1985 Dangerous Goods (Transport by Road or Rail) Regulations 2008 [Part 18] Relevant Legislation and Regulations Dangerous Goods Act 1985 Dangerous Goods (Transport by Road or Rail) Regulations 2008 [Part 18] Regulation Objectives to reduce as far as practicable the risks of personal

More information

On the Q&A to the Guideline for Common Technical Documents

On the Q&A to the Guideline for Common Technical Documents To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare

More information

EudraLex. Part I1 Chapter 6: Quality Control

EudraLex. Part I1 Chapter 6: Quality Control EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality

More information

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. 19 June 2018 CMDh/361/2017, Rev.2 Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to national authorised medicinal products for human use Introduction

More information

European Medicines Agency Inspections

European Medicines Agency Inspections European Medicines Agency Inspections London, 31 March 2006 CHMP/QWP/185401/2004 final COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE REQUIREMENTS TO THE CHEMICAL AND PHARMACEUTICAL

More information

CREATING EUDRAVIGILANCE PRODUCT REPORT MESSAGES: PRODUCT REPORT STEP-BY-STEP GUIDE

CREATING EUDRAVIGILANCE PRODUCT REPORT MESSAGES: PRODUCT REPORT STEP-BY-STEP GUIDE CREATING EUDRAVIGILANCE PRODUCT REPORT MESSAGES: PRODUCT REPORT STEP-BY-STEP GUIDE The WEB Trader allows the users to create and send EudraVigilance Product Report Messages (EVPRMs) containing Product

More information

OFFICIAL CONTROL AUTHORITY BATCH RELEASE (OCABR) OF VACCINES AND BLOOD PRODUCTS

OFFICIAL CONTROL AUTHORITY BATCH RELEASE (OCABR) OF VACCINES AND BLOOD PRODUCTS Division Laboratories (OMCL) OFFICIAL CONTROL AUTHORITY BATCH RELEASE (OCABR) OF VACCINES AND BLOOD PRODUCTS Schweizerisches Heilmittelinstitut Institut suisse des produits thérapeutiques Istituto svizzero

More information

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author

More information

API Inspections in Emerging Markets: The EDQM Experience

API Inspections in Emerging Markets: The EDQM Experience API Inspections in Emerging Markets: The EDQM Experience 18 October 2010 Sträter Life Science Gründungsymposium Dr Florence Benoit-Guyod, EDQM Inspector Certification of Substances Division European Directorate

More information

SAPRAA Meeting Alternative API evaluation processes e.g. Confirmation of WHO API Prequalification - CPQ

SAPRAA Meeting Alternative API evaluation processes e.g. Confirmation of WHO API Prequalification - CPQ SAPRAA Meeting Alternative API evaluation processes e.g. Confirmation of WHO API Prequalification - CPQ Silverani Padayachee O303030 October 201530 30 October 2015 Bytes Conference Centre-Midrand Alternative

More information

CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES

CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES INTRODUCTION: This document describes the requirements of a Variation application submitted for an existing application for registration of medicine

More information

WHO-UNICEF-UNFPA Meeting Copenhagen November 2015

WHO-UNICEF-UNFPA Meeting Copenhagen November 2015 WHO-UNICEF-UNFPA Meeting Copenhagen November 2015 Quality Assessment: Updates Lynda Paleshnuik Lead Quality Assessor 1 Overview Submitting your dossier Before you submit WHO publications and PQ quality

More information

Key-points of Post approval variation in Korea

Key-points of Post approval variation in Korea 7 th APAC, April 10, 2018 Key-points of Post approval variation in Korea Eunkyung Kim, Ph.D. Drug Evaluation Department, NIFDS, MFDS Disclaimer The information in this presentation is based on my experience.

More information

Building Standards Customer Journey

Building Standards Customer Journey Building Standards Customer Journey Are you doing building work or home improvements? If so, this guide is for you. Building Standards Customer Journey Contents 2 Contents Building Standards Customer Journey

More information

REGULATION (EC) No 542/95

REGULATION (EC) No 542/95 REGULATION (EC) No 542/95 Commission Regulation (EC) No 542/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of Council Regulation

More information

COMMON TECHNICAL REQUIREMENTS ACTR. one vision one identity one community

COMMON TECHNICAL REQUIREMENTS ACTR. one vision one identity one community ACTR ASEAN COMMON TECHNICAL REQUIREMENTS ACTR one vision one identity one community ASEAN COMMON TECHNICAL REQUIREMENTS (ACTR) The ASEAN Secretariat Jakarta The Association of Southeast Asian Nations (ASEAN)

More information

API EUROPEAN GMP REQUIREMENTS. Alessio Ferrari

API EUROPEAN GMP REQUIREMENTS. Alessio Ferrari API EUROPEAN GMP REQUIREMENTS Alessio Ferrari SUMMARY GUIDELINES IMPLICATIONS FOR THE INDUSTRY ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC PART I EU GMP Chapter 5 OFFICIAL MEASURES TO PROTECT. PROCEDURE TO

More information

Intermaritime Certification Services (ICS) QUALITY MANAGEMENT SYSTEM INSTRUCTIVE FOR ISM-CODE

Intermaritime Certification Services (ICS) QUALITY MANAGEMENT SYSTEM INSTRUCTIVE FOR ISM-CODE 1.0 TITLE: 2.0 OBJECTIVES This Instructive reflect, as applicable, the IMO Resolution A.1022 (26) "Guidelines on the Implementation of the ISM-Code by Administrations" and the IMO Resolution A.741 (18)

More information

Writing a Convincing Dossier on Impurities and Method Validation. Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products

Writing a Convincing Dossier on Impurities and Method Validation. Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products Writing a Convincing Dossier on Impurities and Method Validation Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products 1 Writing a Convincing Dossier on Impurities and Method Validation

More information